FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893287406> ?p ?o ?g. }

• W2893287406 abstract "Previous studies suggest that multiple sclerosis (MS) patients have a greater stroke risk than the general population but there is limited evidence of stroke risk in patients receiving disease-modifying treatment. We assessed stroke risk in MS patients treated with subcutaneous interferon-β1a (sc IFN-β1a) using pooled data from clinical trials and post-marketing surveillance.Seventeen phase II-IV Merck KGaA-sponsored trials of sc IFN-β1a were assessed to estimate the stroke incidence rate (IR) and IR ratio (IRR) per 100 patient-years (PY), and associated 95% confidence intervals (CI). The association of treatment duration with stroke was assessed through a Cox model. IR, IRR, and hazard ratio (HR) were adjusted by age, sex, presence of any comorbidity, and MS duration. Individual case safety reports were retrieved from the Global Patient Safety Database. The reporting rates of stroke were calculated and classified as medically confirmed or non-medically confirmed according to the source of each report.In 17 clinical trials, 4412 patients were treated with sc IFN-β1a for a total of 10,622 PY and 1055 patients with placebo for 2005 PY. The IR/100 PY (95% CI) of stroke was 0.025 (0.004, 0.150) in sc IFN-β1a patients and 0.051 (0.008, 0.349) in placebo patients. The IRR for sc IFN-β1a vs placebo was 0.486 (0.238, 0.995) and the HR was 0.496 (0.235, 1.043) for time to stroke-related event for sc IFN-β1a treatment at any dose compared with placebo. Among sc IFN-β1a patients, the IRR in those treated for < 2 years was 0.602 (0.159, 2.277) and for ≥ 2 years 0.469 (0.196, 1.124). Analysis of the safety database showed that the overall reporting rate for stroke was 13.286/10,000 PY.Safety data from both clinical trial and post-marketing settings indicate that treatment with sc IFN-β1a does not increase stroke risk in patients with MS.Merck KGaA, Darmstadt, Germany." @default.
• W2893287406 created "2018-10-05" @default.
• W2893287406 creator A5004169404 @default.
• W2893287406 creator A5019985314 @default.
• W2893287406 creator A5029218146 @default.
• W2893287406 creator A5077353912 @default.
• W2893287406 creator A5088215267 @default.
• W2893287406 date "2018-09-25" @default.
• W2893287406 modified "2023-10-18" @default.
• W2893287406 title "Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance" @default.
• W2893287406 cites W1545827176 @default.
• W2893287406 cites W1938188185 @default.
• W2893287406 cites W1978097337 @default.
• W2893287406 cites W1983999022 @default.
• W2893287406 cites W1985662953 @default.
• W2893287406 cites W2004733888 @default.
• W2893287406 cites W2011727358 @default.
• W2893287406 cites W2013331214 @default.
• W2893287406 cites W2020593284 @default.
• W2893287406 cites W2032642468 @default.
• W2893287406 cites W2038054049 @default.
• W2893287406 cites W2046329092 @default.
• W2893287406 cites W2089182484 @default.
• W2893287406 cites W2092120519 @default.
• W2893287406 cites W2095666175 @default.
• W2893287406 cites W2103136116 @default.
• W2893287406 cites W2106654138 @default.
• W2893287406 cites W2112063945 @default.
• W2893287406 cites W2136139191 @default.
• W2893287406 cites W2139367012 @default.
• W2893287406 cites W2142467198 @default.
• W2893287406 cites W2143134934 @default.
• W2893287406 cites W2148814846 @default.
• W2893287406 cites W2152511465 @default.
• W2893287406 cites W2159596132 @default.
• W2893287406 cites W2161425005 @default.
• W2893287406 cites W2163182789 @default.
• W2893287406 cites W2166983650 @default.
• W2893287406 cites W2167980811 @default.
• W2893287406 cites W2169098250 @default.
• W2893287406 cites W2402532842 @default.
• W2893287406 cites W2567190566 @default.
• W2893287406 cites W2613785734 @default.
• W2893287406 cites W2654453124 @default.
• W2893287406 cites W4210548604 @default.
• W2893287406 cites W4210933644 @default.
• W2893287406 cites W4244801936 @default.
• W2893287406 cites W4297966720 @default.
• W2893287406 doi "https://doi.org/10.1007/s12325-018-0790-1" @default.
• W2893287406 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6224000" @default.
• W2893287406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30255416" @default.
• W2893287406 hasPublicationYear "2018" @default.
• W2893287406 type Work @default.
• W2893287406 sameAs 2893287406 @default.
• W2893287406 citedByCount "1" @default.
• W2893287406 countsByYear W28932874062022 @default.
• W2893287406 crossrefType "journal-article" @default.
• W2893287406 hasAuthorship W2893287406A5004169404 @default.
• W2893287406 hasAuthorship W2893287406A5019985314 @default.
• W2893287406 hasAuthorship W2893287406A5029218146 @default.
• W2893287406 hasAuthorship W2893287406A5077353912 @default.
• W2893287406 hasAuthorship W2893287406A5088215267 @default.
• W2893287406 hasBestOaLocation W28932874061 @default.
• W2893287406 hasConcept C120665830 @default.
• W2893287406 hasConcept C121332964 @default.
• W2893287406 hasConcept C126322002 @default.
• W2893287406 hasConcept C127413603 @default.
• W2893287406 hasConcept C142724271 @default.
• W2893287406 hasConcept C167704817 @default.
• W2893287406 hasConcept C203014093 @default.
• W2893287406 hasConcept C204787440 @default.
• W2893287406 hasConcept C207103383 @default.
• W2893287406 hasConcept C27081682 @default.
• W2893287406 hasConcept C2780640218 @default.
• W2893287406 hasConcept C2780645631 @default.
• W2893287406 hasConcept C2908647359 @default.
• W2893287406 hasConcept C44249647 @default.
• W2893287406 hasConcept C535046627 @default.
• W2893287406 hasConcept C61511704 @default.
• W2893287406 hasConcept C71924100 @default.
• W2893287406 hasConcept C78519656 @default.
• W2893287406 hasConcept C99454951 @default.
• W2893287406 hasConceptScore W2893287406C120665830 @default.
• W2893287406 hasConceptScore W2893287406C121332964 @default.
• W2893287406 hasConceptScore W2893287406C126322002 @default.
• W2893287406 hasConceptScore W2893287406C127413603 @default.
• W2893287406 hasConceptScore W2893287406C142724271 @default.
• W2893287406 hasConceptScore W2893287406C167704817 @default.
• W2893287406 hasConceptScore W2893287406C203014093 @default.
• W2893287406 hasConceptScore W2893287406C204787440 @default.
• W2893287406 hasConceptScore W2893287406C207103383 @default.
• W2893287406 hasConceptScore W2893287406C27081682 @default.
• W2893287406 hasConceptScore W2893287406C2780640218 @default.
• W2893287406 hasConceptScore W2893287406C2780645631 @default.
• W2893287406 hasConceptScore W2893287406C2908647359 @default.
• W2893287406 hasConceptScore W2893287406C44249647 @default.
• W2893287406 hasConceptScore W2893287406C535046627 @default.
• W2893287406 hasConceptScore W2893287406C61511704 @default.
• W2893287406 hasConceptScore W2893287406C71924100 @default.
• W2893287406 hasConceptScore W2893287406C78519656 @default.

• next